- Home
- RHI vs HCM Comparison
RHI vs HCM Comparison
Compare RHI & HCM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | RHI | HCM |
|---|---|---|
| Founded | 1948 | 2000 |
| Country | US | |
| Employees | N/A | N/A |
| Industry | Professional Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.8B | 2.7B |
| IPO Year | 1994 | N/A |
Fundamental Metrics
Financial Performance| Metric | RHI | HCM |
|---|---|---|
| Price | $26.03 | $15.16 |
| Analyst Decision | Hold | Sell |
| Analyst Count | 6 | 1 |
| Target Price | ★ $32.17 | $13.75 |
| AVG Volume (30 Days) | ★ 3.7M | 25.6K |
| Earning Date | 04-30-2026 | 01-01-0001 |
| Dividend Yield | ★ 9.11% | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 1.33 | N/A |
| Revenue | ★ $5,378,506,000.00 | N/A |
| Revenue This Year | $1.57 | N/A |
| Revenue Next Year | $5.99 | $16.12 |
| P/E Ratio | $19.41 | ★ $5.49 |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $24.35 | $11.51 |
| 52 Week High | $61.16 | $19.50 |
Technical Indicators
Market Signals| Indicator | RHI | HCM |
|---|---|---|
| Relative Strength Index (RSI) | 42.28 | 52.34 |
| Support Level | $24.35 | $14.68 |
| Resistance Level | $33.20 | $15.20 |
| Average True Range (ATR) | 1.96 | 0.38 |
| MACD | -0.63 | -0.03 |
| Stochastic Oscillator | 15.32 | 73.68 |
Price Performance
Historical ComparisonAbout RHI Robert Half Inc.
Robert Half Inc was founded in 1948, Robert Half provides temporary, permanent, and outcome-based staffing for both in-person and remote positions in the finance and accounting, technology, legal, marketing, and administrative fields. Its subsidiary consulting arm, Protiviti, specializes in technology, risk, auditing, and compliance matters. The firm generates its sales inside the U.S. and is one of the specialized firms in the fragmented U.S. staffing industry. The firm generates annual revenue of around $7 billion.
About HCM HUTCHMED (China) Limited
HUTCHMED (China) Ltd is an biopharmaceutical company engaged in the discovery, development, and commercialization of targeted therapies and immunotherapies for the treatment of cancer and immunological diseases. The company has a portfolio of several cancer drug candidates currently in clinical studies around the world and extensive commercial infrastructure in its home market of China. The company operates in two reportable segments Oncology/Immunology, and Other Ventures.